| Title: |
ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium |
| Authors: |
Vajapeyam, S; Brown, D; Ziaei, A; Wu, S; Vezina, G; Stern, JS; Panigrahy, A; Patay, Z; Tamrazi, B; Jones, JY; Haque, SS; Enterline, DS; Cha, S; Jones, BV; Yeom, KW; Onar-Thomas, A; Dunkel, IJ; Fouladi, M; Fangusaro, JR; Poussaint, TY |
| Source: |
American Journal of Neuroradiology, vol 43, iss 3 |
| Publisher Information: |
eScholarship, University of California |
| Publication Year: |
2022 |
| Collection: |
University of California: eScholarship |
| Subject Terms: |
32 Biomedical and Clinical Sciences (for-2020); 3202 Clinical Sciences (for-2020); 3211 Oncology and Carcinogenesis (for-2020); Clinical Research (rcdc); Neurosciences (rcdc); Orphan Drug (rcdc); Cancer (rcdc); Pediatric Cancer (rcdc); Pediatric (rcdc); Rare Diseases (rcdc); Brain Disorders (rcdc); Neurofibromatosis (rcdc); Brain Cancer (rcdc); 6.1 Pharmaceuticals (hrcs-rac); Cancer (hrcs-hc); Benzimidazoles (mesh); Brain Neoplasms (mesh); Child (mesh); Diffusion Magnetic Resonance Imaging (mesh); Glioma (mesh); Humans (mesh); Neurofibromatosis 1 (mesh); Proto-Oncogene Proteins B-raf (mesh); 1103 Clinical Sciences (for); 1109 Neurosciences (for); Nuclear Medicine & Medical Imaging (science-metrix); 3209 Neurosciences (for-2020); 3406 Physical chemistry (for-2020) |
| Subject Geographic: |
455 - 461 |
| Description: |
BACKGROUND AND PURPOSE: Selumetinib is a promising MAP (mitogen-activated protein) kinase (MEK) 1/2 inhibitor treatment for pediatric low-grade gliomas. We hypothesized that MR imaging-derived ADC histogram metrics would be associated with survival and response to treatment with selumetinib. MATERIALS AND METHODS: Children with recurrent, refractory, or progressive pediatric low-grade gliomas who had World Health Organization grade I pilocytic astrocytoma with KIAA1549-BRAF fusion or the BRAF V600E mutation (stratum 1), neurofibromatosis type 1-associated pediatric low-grade gliomas (stratum 3), or sporadic non-neurofibromatosis type 1 optic pathway and hypothalamic glioma (OPHG) (stratum 4) were treated with selumetinib for up to 2 years. Quantitative ADC histogram metrics were analyzed for total and enhancing tumor volumes at baseline and during treatment. RESULTS: Each stratum comprised 25 patients. Stratum 1 responders showed lower values of SD of baseline ADC_total as well as a larger decrease with time on treatment in ADC_total mean, mode, and median compared with nonresponders. Stratum 3 responders showed a greater longitudinal decrease in ADC_total. In stratum 4, higher baseline ADC_total skewness and kurtosis were associated with shorter progression-free survival. When all 3 strata were combined, responders showed a greater decrease with time in ADC_total mode and median. Compared with sporadic OPHG, neurofibromatosis type 1-associated OPHG had lower values of ADC_total mean, mode, and median as well as ADC_enhancement mean and median and higher values of ADC_total skewness and kurtosis at baseline. The longitudinal decrease in ADC_total median during treatment was significantly greater in sporadic OPHG compared with neurofibromatosis type 1-associated OPHG. CONCLUSIONS: ADC histogram metrics are associated with progression-free survival and response to treatment with selumetinib in pediatric low-grade gliomas. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
unknown |
| Relation: |
qt5xx4n957; https://escholarship.org/uc/item/5xx4n957; https://escholarship.org/content/qt5xx4n957/qt5xx4n957.pdf |
| DOI: |
10.3174/ajnr.a7433 |
| Availability: |
https://escholarship.org/uc/item/5xx4n957; https://escholarship.org/content/qt5xx4n957/qt5xx4n957.pdf; https://doi.org/10.3174/ajnr.a7433 |
| Rights: |
public |
| Accession Number: |
edsbas.69430DCA |
| Database: |
BASE |